Comparison of digital and analog [
Humans
Male
Prostatic Neoplasms
/ surgery
Prostatectomy
Positron Emission Tomography Computed Tomography
/ methods
Aged
Prospective Studies
Gallium Radioisotopes
Middle Aged
Neoplasm Recurrence, Local
/ diagnostic imaging
Gallium Isotopes
Prostate-Specific Antigen
/ blood
Edetic Acid
/ analogs & derivatives
Oligopeptides
Biochemical recurrence
Detection rate
Positron emission tomography
Prostate cancer
Prostate-specific membrane antigen
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 07 2024
01 07 2024
Historique:
received:
07
10
2023
accepted:
19
06
2024
medline:
2
7
2024
pubmed:
2
7
2024
entrez:
1
7
2024
Statut:
epublish
Résumé
Digital positron emission tomography/computed tomography (PET/CT) has shown enhanced sensitivity and spatial resolution compared with analog PET/CT. The present study compared the diagnostic performance of digital and analog PET/CT with [
Identifiants
pubmed: 38951530
doi: 10.1038/s41598-024-65399-1
pii: 10.1038/s41598-024-65399-1
doi:
Substances chimiques
Gallium Radioisotopes
0
Gallium Isotopes
0
gallium 68 PSMA-11
0
Prostate-Specific Antigen
EC 3.4.21.77
Edetic Acid
9G34HU7RV0
Oligopeptides
0
PSMA-11
0
Types de publication
Journal Article
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
14989Subventions
Organisme : Ministry of Health and Welfare
ID : HR18C0016
Organisme : Ministry of Health and Welfare
ID : HR18C0016
Organisme : Ministry of Health and Welfare
ID : HR18C0016
Organisme : Ministry of Health and Welfare
ID : HR18C0016
Organisme : Ministry of Health and Welfare
ID : HR18C0016
Organisme : Ministry of Health and Welfare
ID : HR18C0016
Organisme : Ministry of Health and Welfare
ID : HR18C0016
Informations de copyright
© 2024. The Author(s).
Références
Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17–48 (2023).
doi: 10.3322/caac.21763
pubmed: 36633525
Brawley, S., Mohan, R. & Nein, C. D. Localized prostate cancer: Treatment options. Am. Fam. Physician. 97, 798–805 (2018).
pubmed: 30216009
Paller, C. J. & Antonarakis, E. S. Management of biochemically recurrent prostate cancer after local therapy: Evolving standards of care and new directions. Clin. Adv. Hematol. Oncol. 11, 14–23 (2013).
pubmed: 23416859
pmcid: 3624708
Zhang-Yin, J., Montravers, F., Montagne, S., Hennequin, C. & Renard-Penna, R. Diagnosis of early biochemical recurrence after radical prostatectomy or radiation therapy in patients with prostate cancer: State of the art. Diagn. Interv. Imaging. 103, 191–199 (2022).
doi: 10.1016/j.diii.2022.02.005
pubmed: 35227633
Maurer, T., Eiber, M., Schwaiger, M. & Gschwend, J. E. Current use of PSMA-PET in prostate cancer management. Nat. Rev. Urol. 13, 226–235 (2016).
doi: 10.1038/nrurol.2016.26
pubmed: 26902337
Zimmerman, M. E., Meyer, A. R., Rowe, S. P. & Gorin, M. A. Imaging of prostate cancer with positron emission tomography. Clin. Adv. Hematol. Oncol. 17, 455–463 (2019).
pubmed: 31449514
Schwarzenboeck, S. M. et al. PSMA ligands for PET imaging of prostate cancer. J. Nucl. Med. 58, 1545–1552 (2017).
doi: 10.2967/jnumed.117.191031
pubmed: 28687599
Farolfi, A. et al. (68)Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy. Eur. J. Nucl. Med. Mol. Imaging. 46, 11–19 (2019).
Sonni, I. et al. Initial experience with a SiPM-based PET/CT scanner: Influence of acquisition time on image quality. EJNMMI Phys. 5, 9 (2018).
doi: 10.1186/s40658-018-0207-x
pubmed: 29666972
pmcid: 5904089
Schillaci, O. & Urbano, N. Digital PET/CT: A new intriguing chance for clinical nuclear medicine and personalized molecular imaging. Eur. J. Nucl. Med. Mol. Imaging. 46, 1222–1225 (2019).
doi: 10.1007/s00259-019-04300-z
pubmed: 30859431
Fuentes-Ocampo, F. et al. Digital versus analog PET/CT in patients with known or suspected liver metastases. Nucl. Med. Commun. 42, 421–428 (2021).
doi: 10.1097/MNM.0000000000001341
pubmed: 33306635
López-Mora, D. A. et al. Superior performance of 18F-fluorocholine digital PET/CT in the detection of parathyroid adenomas. Eur. J. Nucl. Med. Mol. Imaging. 47, 572–578 (2020).
doi: 10.1007/s00259-020-04680-7
pubmed: 31919634
Alberts, I. et al. Digital versus analogue PET in [(68)Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer: A matched-pair comparison. Eur. J. Nucl. Med. Mol. Imaging. 47, 614–623 (2020).
doi: 10.1007/s00259-019-04630-y
pubmed: 31792572
Alberts, I. et al. The influence of digital PET/CT on diagnostic certainty and interrater reliability in [(68)Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer. Eur. Radiol. 31, 8030–8039 (2021).
doi: 10.1007/s00330-021-07870-5
pubmed: 33856522
pmcid: 8452558
Karp, J. S., Surti, S., Daube-Witherspoon, M. E. & Muehllehner, G. Benefit of time-of-flight in PET: Experimental and clinical results. J. Nucl. Med. 49, 462–470 (2008).
doi: 10.2967/jnumed.107.044834
pubmed: 18287269
Surti, S. Update on time-of-flight PET imaging. J. Nucl. Med. 56, 98–105 (2015).
doi: 10.2967/jnumed.114.145029
pubmed: 25525181
López-Mora, D. A., Carrió, I. & Flotats, A. Digital PET vs analog PET: Clinical implications?. Semin. Nucl. Med. 52, 302–311 (2022).
doi: 10.1053/j.semnuclmed.2021.10.004
pubmed: 34836617
van Sluis, J. et al. Performance characteristics of the digital biograph vision PET/CT system. J. Nucl. Med. 60, 1031–1036 (2019).
doi: 10.2967/jnumed.118.215418
pubmed: 30630944
Ma, W., Mao, J., Yang, J., Wang, T. & Zhao, Z. H. Comparing the diagnostic performance of radiotracers in prostate cancer biochemical recurrence: A systematic review and meta-analysis. Eur. Radiol. 32, 7374–7385 (2022).
doi: 10.1007/s00330-022-08802-7
pubmed: 35486169
pmcid: 9668945
Fendler, W. P. et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: A prospective single-arm clinical trial. JAMA Oncol. 5, 856–863 (2019).
doi: 10.1001/jamaoncol.2019.0096
pubmed: 30920593
pmcid: 6567829
Fendler, W. P. et al. (68)Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur. J. Nucl. Med. Mol. Imaging. 44, 1014–1024 (2017).
doi: 10.1007/s00259-017-3670-z
pubmed: 28283702
Fendler, W. P. et al. PSMA PET/CT: Joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur. J. Nucl. Med. Mol. Imaging. 50, 1466–1486 (2023).
doi: 10.1007/s00259-022-06089-w
pubmed: 36604326
pmcid: 10027805
Perera, M. et al. Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: A systematic review and meta-analysis. Eur. Urol. 70, 926–937 (2016).
doi: 10.1016/j.eururo.2016.06.021
pubmed: 27363387
Calais, J. et al. Impact of (68)Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence. J. Nucl. Med. 59, 434–441 (2018).
doi: 10.2967/jnumed.117.202945
pubmed: 29242398
pmcid: 5868499
Grubmüller, B. et al. (68)Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy—Diagnostic performance and impact on therapeutic decision-making. Eur. J. Nucl. Med. Mol. Imaging. 45, 235–242 (2018).
doi: 10.1007/s00259-017-3858-2
pubmed: 29075832
Farolfi, A. et al. Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer. J. Nucl. Med. 62, 596–604 (2021).
doi: 10.2967/jnumed.120.257238
pubmed: 33712536
Koopman, D. et al. Performance of digital PET compared with high-resolution conventional PET in patients with cancer. J. Nucl. Med. 61, 1448–1454 (2020).
doi: 10.2967/jnumed.119.238105
pubmed: 32060217
Nguyen, N. C. et al. Image quality and diagnostic performance of a digital PET prototype in patients with oncologic diseases: Initial experience and comparison with analog PET. J. Nucl. Med. 56, 1378–1385 (2015).
doi: 10.2967/jnumed.114.148338
pubmed: 26159588
Adams, M. C. et al. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am. J. Roentgenol. 195, 310–320 (2010).
doi: 10.2214/AJR.10.4923
pubmed: 20651185
Ceci, F. et al. (68)Ga-PSMA-11 PET/CT in recurrent prostate cancer: Efficacy in different clinical stages of PSA failure after radical therapy. Eur. J. Nucl. Med. Mol. Imaging. 46, 31–39 (2019).
doi: 10.1007/s00259-018-4189-7
pubmed: 30350010